Minocycline in acne system therapy
- Authors: Samtsov A.V.1
-
Affiliations:
- S. M. Kirov Military Medical Academy
- Issue: Vol 96, No 1 (2020)
- Pages: 67-71
- Section: DRUG TREATMENT IN DERMATOVENEROLOGY
- URL: https://journals.rcsi.science/0042-4609/article/view/117032
- DOI: https://doi.org/10.25208/vdv1105-2020-96-1-67-71
- ID: 117032
Cite item
Full Text
Abstract
Systemic antibiotics in combination with topical retinoids and benzoyl peroxide are first-line drugs for the treatment of moderate to severe acne. The systemic antibiotic Minocycline has a wide spectrum of action against gram + and gram-organisms, including strains resistant to penicillins and cephalosporins. A pronounced bacteriostatic effect is achieved by a high level of lipophilicity, rapid penetration through the lipid layer of bacteria and intensive accumulation in the sebaceous glands. Minolexin® is a highly effective and safe medication for the treatment of moderate to severe acne and can be recommended for practical use in outpatient practice.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Aleksey V. Samtsov
S. M. Kirov Military Medical Academy
Author for correspondence.
Email: avsamtsov@mail.ru
Dr. Sci. (Med.)., Prof., Head of the Department of Skin and Sexually Transmitted Diseases
Russian Federation, Akademika Lebedeva str., 6, Saint Petersburg, 194044References
- Zaenglein А., Pathy А., Schlosser В. et al. Guidelines of care for the management of acne vulgaris. J Am AcadDermatol. 2016; 74: 945—973.
- Straight Ch., Lee H., Liu G., Kirby J. Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guide line recommend ations and opportunities for cost-savings. J Am Acad Dermatol. 2015; 72: 822—827.
- Garrido-Mesa N., Zarzuelo A., Galves J. Minocycline far beyond an antibiotic. Br J Dermatol. 2013; 109: 337—352.
- Gollnick H., Dreno B. Pathophysiology and management of acne. 2015; 29 (Suppl. 4), 3—11.
- Strauss J., Krowchuk D., Leyden J. et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651—663.
- Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013; 17: 114—122.
- Leyden J.J., Del Rosso J.Q. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol 2011; 4: 40—47.
- Torok H.M. Extended-release formulation of minocycline in the treatment of moderate-to-severe acne vulgaris in patients over the age of 12 years. J Clin Aesthet Dermatol. 2013; 6: 19—22.
- Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013; 17: 114—22.
- Thiboutot D., Dreno B., Abanmi A. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2018; 78: 21—23.
- Stewart D., Torok H., Weiss J., Plott R. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006; 78 (4Suppl): 11—20.
- Torok H.M. Extended-release Formulation of Minocycline in the Treatment of Moderate-to-severe Acne Vulgaris in Patients over the Age of 12 Years. J Clin Aesthet Dermatol. 2013 Jul; 6: 19—22.
- Ochsendorf F. Systemic antibiotic therapy of acnevulgaris. J. Dtsch. Dermatol. Ges. 2006; 4: 828—41.
- Leyden J.J., Del Rosso J.Q. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J. Clin. Aesthet. Dermatol. 2011; 4: 40—7.
- Snarskaya E.S. Antibacterial therapy of vulgar acne. Vestn Dermatol. 2019; 95: 58—67.
Supplementary files
